IgA and IgG hypogammaglobulinemia in Waldenstrom's macroglobulinemia

Hunter, Zachary; Manning, R.J.; Hanzis, Christine; Ciccarelli, Bryan; Ioakimidis, Leukothea; Patterson, Christopher J.; Lewicki, Megan; Tseng, Hsuiyi; Gong, Ping; Liu, Xia; Zhou, Yangsheng; Yang, Guang; Sun, Junzhe; Liu, Xu; Sheehy, Patricia; Morra, Massimo; Treon, Steven P.

doi:10.3324/haematol.2009.010348

Cited by 48 publications

(36 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is clear that the major immunological defect in MM and Waldenström macroglobulinemia (WM) patients is in the humoral system, with a diminished production of polyclonal immunoglobulins which leads to a defective antibody response. 1,14,15 In MGUS, prior studies report that hypogammaglobulinemia is present in 25-28% of the cases. 9,16 Interestingly, in contrast to MM and WM, in the MGUS study from Denmark, presence of hypogammaglobulinemia was not associated with an increased risk of bacteremia.…”

Section: Resultsmentioning

confidence: 99%

Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study

Kristinsson¹,

Tang²,

Pfeiffer³

et al. 2011

Haematologica

120

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study

Kristinsson¹,

Tang²,

Pfeiffer³

et al. 2011

Haematologica

120

View full text Add to dashboard Cite

“…32 The data from Hunter et al 31 show that low levels of background immunoglobulins in WM may reflect an underlying defect in these patients and provide a clue to pathogenesis. Further studies will help to unravel this "chicken-egg" dilemma.…”

Section: Immunoglobulin M Antibodies To Neural Antigensmentioning

confidence: 99%

“…A study by Hunter et al, reported in this issue of this journal, extends the hypogammaglobulinemia findings. 31 These investigators showed that approximately half their WM patients had hypogammaglobulinemia for the "uninvolved" immunoglobulins (IgG, IgA). These reduced levels of background normal immunoglobulins did not appear to predispose to bacterial infections, nor did they improve with effective treatment of the WM.…”

Section: Immunoglobulin M Antibodies To Neural Antigensmentioning

confidence: 99%

Pathophysiology of Waldenstrom's macroglobulinemia

Stone¹,

Pascual²

2010

Haematologica

View full text Add to dashboard Cite

“…39 IgG and IgA hypogammaglobulinemia may occur simultaneously with monoclonal IgM hypergammaglobulinemia, which can contribute to recurrent respiratory tract infections, but its cause is not well understood and could be associated with alterations in the development of plasma cells and/or the production of immunoglobulins. 40 LPL primarily involves the bone marrow, but the disease can reach the lymph nodes, spleen and liver, among other organs. Lymphoplasmocytoid/plasmacytic infiltration is responsible for asthenia, fatigue, recurrent fever, night sweats, weight loss, cytopenia, lymphadenopathy and organomegaly.…”

Section: Clinical Symptomsmentioning

confidence: 99%

Waldenström's macroglobulinemia - a review

Coimbra

Neves

Lima

et al. 2014

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

Waldenström's macroglobulinemia (WM) is a lymphoproliferative disease of B lymphocytes, characterized by a lymphoplasmocytic lymphoma in the bone marrow and by IgM monoclonal hypergammaglobulinemia. It was first described in 1944 by Jan Gösta Waldenström, reporting two patients with oronasal bleeding, lymphadenopathy, anemia, thrombocytopenia, high erythrocyte sedimentation rate and serum viscosity, normal radiography and bone marrow infiltrated by lymphoid cells. The WM is a rare disease with a typically indolent clinical course, affecting mainly individuals aged between 63 and 68 years. Most patients have clinical signs and symptoms related to hyperviscosity resulting from IgM monoclonal gammopathy, and/or cytopenias resulting from bone marrow infiltration by lymphoma. The differential diagnosis with other lymphomas is essential for the assessment of prognosis and therapeutic approach. Treatment of patients with asymptomatic WM does not improve the quality of life of patients, or increase their survival, being recommended, therefore, their follow-up. For the treatment of symptomatic patients, alkylating agents, purine analogs and anti-CD20 monoclonal antibodies are used. However, the disease is incurable and the response to therapy is not always favorable. Recent studies have shown promising results with bortezomib, an inhibitor of proteasomes, and some patients respond to thalidomide. In patients with relapse or refractory to therapy, autologous transplantation may be indicated. The aim of this paper is to describe in detail the current knowledge on the pathophysiology of WM, main clinical manifestations, diagnosis, prognosis and treatment.

show abstract

IgA and IgG hypogammaglobulinemia in Waldenstrom's macroglobulinemia

Cited by 48 publications

References 24 publications

Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study

Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study

Pathophysiology of Waldenstrom's macroglobulinemia

Waldenström's macroglobulinemia - a review

Contact Info

Product

Resources

About